Proteomics International Laboratories (PIQ) Investor Presentation summary

Company overview and financials

• Focuses on predictive diagnostics and precision medicine, leveraging proprietary Promarker platform technology.

• Market capitalisation of A$78m, cash of ~A$6.6m as of June 2024, and A$2.7m revenue forecast for FY25.

• Top 40 shareholders hold 53%, directors hold 14%, and a recent institutional placement raised $6.5m.

• Accredited laboratories and bioanalytical services generate revenue, offsetting cash burn.

• Recruiting to accelerate commercialisation of three lead diagnostic tests.

Product pipeline and technology

• PromarkerD (diabetic kidney disease), PromarkerEndo (endometriosis), and PromarkerEso (esophageal cancer) are lead tests, all with high accuracy and large target populations.

• Promarker platform enables identification of unique protein biomarkers for novel diagnostics.

• Additional pipeline includes tests for oxidative stress, asthma, COPD, diabetic retinopathy, and neuropathy.

• OxiDx, a spin-out, is developing a world-first oxidative stress blood test for sports and veterinary use.

Market opportunity and unmet needs

• 10.5% of adults globally have diabetes; 1 in 9 women have endometriosis; 1-2% of western populations at risk of esophageal cancer.

• PromarkerD can predict chronic kidney disease up to 4 years in advance with 86% accuracy.

• PromarkerEndo and PromarkerEso both show ~90% accuracy in late-stage development.

• Early detection and intervention can save healthcare systems billions and improve patient outcomes.